The assay is intended for use to help guide health care professionals in cancer treatment management for patients with various solid tumors in accordance with professional guidelines. The identification of genomic variants and key genomic signature biomarkers, including tumor mutation burden (TMB) and microsatellite instability (MSI), will identify patients who may benefit from treatment with specific FDA-approved targeted therapies, or in the use of other targeted oncology therapies. The results may also identify patient opportunities for participation in clinical trials.
Reference Range
No variants detected
Clinical Utility
The assay is intended for use to help guide health care professionals in cancer treatment management for patients with various solid tumors in accordance with professional guidelines. The identification of genomic variants and key genomic signature biomarkers, including tumor mutation burden (TMB) and microsatellite instability (MSI), will identify patients who may benefit from treatment with specific FDA-approved targeted therapies, or in the use of other targeted oncology therapies. The results may also identify patient opportunities for participation in clinical trials.
CPT Codes
81455
Methodology
Next Gen Sequencing
Testing Schedule
Routine, Mon-Fri
Report Availability
14 days
Container
FFPE
Minimum Volume
>10% Tumor Cells
Reference Range
No variants detected
Full View
CPT Codes
81455
Methodology
Next Gen Sequencing
Testing Schedule
Routine, Mon-Fri
Report Availability
14 days
Minimum Volume
>10% Tumor Cells
Container
FFPE
Clinical Utility
The assay is intended for use to help guide health care professionals in cancer treatment management for patients with various solid tumors in accordance with professional guidelines. The identification of genomic variants and key genomic signature biomarkers, including tumor mutation burden (TMB) and microsatellite instability (MSI), will identify patients who may benefit from treatment with specific FDA-approved targeted therapies, or in the use of other targeted oncology therapies. The results may also identify patient opportunities for participation in clinical trials.
Reference Range
No variants detected
Overview
Clinical Utility
The assay is intended for use to help guide health care professionals in cancer treatment management for patients with various solid tumors in accordance with professional guidelines. The identification of genomic variants and key genomic signature biomarkers, including tumor mutation burden (TMB) and microsatellite instability (MSI), will identify patients who may benefit from treatment with specific FDA-approved targeted therapies, or in the use of other targeted oncology therapies. The results may also identify patient opportunities for participation in clinical trials.
